NitroMed said early Tuesday that its chief executive officer and chief financial officer have both resigned.
In a release, the cardiac drug maker said that Michael Loberg has stepped down from his positions as president, chief executive officer and as a director, effective immediately.
NitroMed's chief financial officer, Lawrence Bloch, has also left the company.
The company have given no reason for the resignations.
Insider awaits your enlightening emails: pharmagossip@hotmail.co.uk
No comments:
Post a Comment